102,100 Shares in Charles River Laboratories International, Inc. (CRL) Acquired by APG Asset Management N.V.

APG Asset Management N.V. purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 102,100 shares of the company’s stock, valued at approximately $11,029,000. APG Asset Management N.V. owned 0.21% of Charles River Laboratories International as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently modified their holdings of CRL. BlackRock Inc. grew its holdings in shares of Charles River Laboratories International by 12,573.1% in the 1st quarter. BlackRock Inc. now owns 3,845,643 shares of the company’s stock worth $345,915,000 after acquiring an additional 3,815,298 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Charles River Laboratories International in the 2nd quarter worth $65,915,000. FMR LLC grew its holdings in shares of Charles River Laboratories International by 23.8% in the 2nd quarter. FMR LLC now owns 3,079,179 shares of the company’s stock worth $311,458,000 after acquiring an additional 591,066 shares during the last quarter. FIL Ltd grew its holdings in shares of Charles River Laboratories International by 325.4% during the second quarter. FIL Ltd now owns 417,465 shares of the company’s stock valued at $42,227,000 after buying an additional 319,324 shares in the last quarter. Finally, Koch Industries Inc. purchased a new position in shares of Charles River Laboratories International during the second quarter valued at $240,000. Institutional investors own 97.27% of the company’s stock.

In other news, insider David Ross Smith sold 2,552 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of C$67.10, for a total value of C$171,239.20. Following the transaction, the insider now owns 11,671 shares of the company’s stock, valued at approximately C$783,124.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider William D. Barbo sold 4,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of C$99.91, for a total transaction of C$399,640.00. Following the completion of the sale, the insider now owns 20,424 shares of the company’s stock, valued at approximately C$2,040,561.84. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 10,500 shares of company stock worth $2,885 and have sold 18,699 shares worth $1,892,393. 2.20% of the stock is currently owned by corporate insiders.

A number of research analysts have recently weighed in on the company. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Barclays PLC reissued a “hold” rating and set a $102.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. ValuEngine cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday. Robert W. Baird reissued a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research report on Friday, September 1st. Finally, Bank of America Corporation reduced their price objective on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of C$105.77.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at C$102.12 on Friday. Charles River Laboratories International, Inc. has a 12 month low of C$69.51 and a 12 month high of C$119.05. The firm has a market capitalization of $4,836.61, a P/E ratio of 20.06, a PEG ratio of 1.64 and a beta of 0.94. The company has a quick ratio of 1.49, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The company reported C$1.30 EPS for the quarter, topping the consensus estimate of C$1.22 by C$0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of C$464.23 million for the quarter, compared to the consensus estimate of C$458.93 million. During the same period in the previous year, the business earned $1.18 EPS. Charles River Laboratories International’s revenue was up 9.0% compared to the same quarter last year. sell-side analysts predict that Charles River Laboratories International, Inc. will post 5.12 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “102,100 Shares in Charles River Laboratories International, Inc. (CRL) Acquired by APG Asset Management N.V.” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/apg-asset-management-n-v-takes-position-in-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply